- Details
- In this presentation from Dan Petrylak, MD discusses the recent ARCHES study and offers an insightful perspective into radiographic progression-free survival (rPFS), in prostate cancer. The ARCHES study was a randomized phase 3 study of metastatic hormone-sensitive patients, looking at androgen deprivation therapy (ADT) with Enzalutamide, with a concurrent control group given a placebo, while also...
|
- Details
- Alicia Morgans with Arun Azad and Declan Murphy about an ongoing clinical trial exploring the use of Lutetium PSMA for treating newly diagnosed metastatic hormone-sensitive prostate cancer. Dr. Azad reveals that the trial aims to assess whether adding Lutetium PSMA to standard chemo-hormonal therapy improves efficacy. The study has garnered significant interest, enrolling over a quarter of its tar...
|
- Details
- In a conversation with Alicia Morgans on clinical characteristics of patients with metastatic hormone-sensitive prostate cancer (mHSPC) and identifying subsets of patients to improve personalized treatments, Christopher Sweeney shares data from a European Urology publication Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androge...
|
- Details
- Joining Thomas Keane, MBBCh, FRCSI, FACS, diving into the data reported in the Phase III HERO trial is Bertrand Tombal, MD, PhD. In this conversation, Dr. Tombal drives awareness in the urology community on the use of oral relugolix and the benefits to patients. He discusses the clinical implications of the trial data, intermittent androgen deprivation therapy, the relevance of testosterone surge,...
|
- Details
- In 2019 the first interim analysis of the phase III TITAN trial was reported which led to the approval of apalutamide for metastatic castration-sensitive prostate cancer (mCSPC). In this conversation with Alicia Morgans, MD, MPH, Neeraj Agarwal, MD highlights the final overall survival analysis after a median follow-up of 44 months (nearly 4-years) and the recent final survival analysis Journal of...
|
- Details
- Matthew Deek and Phuoc Tran join Charles Ryan to discuss their recent paper "The Mutational Landscape of Metastatic Castration-Sensitive Prostate Cancer: The Spectrum Theory Revisited" published in European Urology. The aim of this study was to characterize the somatic mutational landscape across the disease spectrum of metastatic castration-sensitive prostate cancer (mCSPC) to elucidate a biologi...
|
- Details
- Michael Morris, MD, and Christopher Sweeney, MBBS join Alicia Morgans, MD, MPH in a discussion on the treatment of metastatic hormone-sensitive prostate cancer. Dr. Sweeney shares his perspective on the use of combination therapy, in addition to traditional ADT, and how he approaches treatment decisions Dr. Morris discusses the latest data in this space coming from the CHAARTED and STAMPEDE studie...
|
- Details
- Tom Keane welcomes Evan Yu to discuss the newest therapeutic options for patients with metastatic hormone-sensitive prostate cancer. Dr. Yu details the most crucial studies to date demonstrating improved OS in mHSPC patients, including the ARCHES , ENZAMET , STAMPEDE , and TITAN clinical trials. Additionally, he touches on the survival benefit shown in the CHAARTED trial. Dr. Yu provides a compreh...
|
- Details
- Hannah Rush joins Alicia Morgans discussing the quality of life outcomes we have seen from patients receiving docetaxel or abiraterone in the STAMPEDE trial. STAMPEDE is a multi-arm, multi-stage trial investigating various therapeutic strategies for the management of locally advanced or metastatic hormone-naïve prostate cancer. In recent years, both docetaxel and abiraterone have been shown to imp...
|
- Details
- Christopher Sweeney joins Charles Ryan to discuss the topic of hormone-sensitive prostate cancer, specifically concentrating on how clinicians can confront and categorize their patients with the disease. In continuing the ongoing conversation of the optimal approach for a high-volume patient, Dr. Sweeney uses evidence from current clinical trials to outline optional alternatives to abiraterone tre...
|
